S ince their first identification more than a decade ago (1), endothelial progenitor cells (EPCs) have been extensively studied for their ability to repair damaged vessel walls and to form new vasculature (2) . EPCs are the lineage-specific stem cells that are mobilized from the bone marrow to peripheral blood in response to traumatic, inflammatory, and ischemic injury (3) (4) (5) . They are defined as a subpopulation of CD34 ϩ hematopoietic cells that express CD133 and vascular endothelial growth factor receptor 2 (6) and are capable of proliferation and differentiation into mature endothelial cells (6, 7) . CD133 is predominantly expressed on "early" EPCs and lost over time when cells begin to express von Willebrand factor, a multimeric adhesion molecule that is synthesized in mature endothelial cells and stored in the Weibel Palade bodies (6, 8, 9) . It is because of this ability that EPCs have been increasingly recognized as a key cellular component for vascular repairs after injury (2, 9, 10) .
Upon vascular injury, EPCs are mobilized from the bone marrow to blood circulation to eventually "home" to the site of injury. Platelets play an active role in the EPC homing and subsequent differentiation (11) (12) (13) . Consistent with such a role, the levels of circulating EPCs rapidly increase in a variety of pathologic conditions, including diabetes, systemic lupus erythematosus, chronic renal failure, rheumatoid arthritis, cancer, coronary artery disease (including vascular stenting), and trauma (14) . Systemic in-flammation is the common characteristic shared among these rather diverse clinical conditions, indicating that stress may be a trigger for EPC mobilization. However, the clinical significance of circulating EPCs in traumatic brain injury (TBI), the acute and most dramatic stress, remains largely unknown.
Vascular repair in TBI-induced brain damage may be more important than other organs because brain is most sensitive to ischemic injury occurring secondary to mechanical impacts. We have recently demonstrated that EPCs in peripheral blood undergo bidirectional changes in patients with TBI in a smaller cohort of 29 patients (15) . However, the number of patients recruited to the study is insufficient to conduct statistical analyses based on the clinical course and prognosis. More importantly, the extent of traumatic injury varies among patients and the variation is further compounded with differential treatments, both of which could have a significant impact on EPC levels and reactivity in peripheral blood and at the site of vascular injury. To address these issues, we have expanded our initial study to include Objective: Endothelial progenitor cells play an active role in vascular repair and revascularization of tissue damaged by traumatic, inflammatory, and ischemic injures. We correlate the changes in circulating endothelial progenitor cells with the severity of traumatic brain injury. The study is designed to investigate the endothelial progenitor cell mobilization after injury and a potential use of circulating endothelial progenitor cells as a prognostic marker for evaluating trauma severity and clinical outcomes.
Design: A prospective cohort study conducted in two neurosurgical intensive care units of Tianjin Medical University General Hospital and Tianjin Huanhu Hospital (Tianjin, China).
Patients: Patients with traumatic brain injury and age-and gender-matched healthy controls.
Interventions: None.
Measurements and Main Results:
Changes in the levels of circulating endothelial progenitor cells were monitored for up to 21 days in 84 patients with traumatic brain injury. Results were correlated with the clinical assessment of injury severity as determined by the Glasgow Coma Scale. The level of circulating endothelial progenitor cells was found to be suppressed 24 -48 hrs after injury but rapidly increased, reaching the highest at days 5-7 post-trauma. Circulating endothelial progenitor cells in patients with improved Glasgow Coma Scale scores were significantly higher than those with deteriorated conditions and remained persistently low in patients who died of trauma.
Conclusions: The results suggest that the level of circulating endothelial progenitor cells correlates with the clinical severity and outcome of traumatic brain injury and may offer potential as a prognostic marker for traumatic brain injury. A long-term follow-up of these patients is ongoing. (Crit Care Med 2011; 39: 1760 -1765)
KEY WORDS: endothelial progenitor cells; traumatic brain injury; clinical outcome; prognostic marker more patients (101 were recruited and 84 finally analyzed). The larger sample size allowed us to conduct subgroup analysis to determine whether circulating EPC levels correlate with clinical TBI prognosis during a follow-up period of up to 21 days.
MATERIALS AND METHODS
Patients. Patients with TBI who were admitted to Tianjin Medical University General Hospital and Tianjin Huanhu Hospital (Tianjin, China) from April 2006 to March 2007 were enrolled. The exclusion criteria include patients with complex trauma involving body trunk and limbs, hematologic disorders, and cancer and patients on sedation. A total of 101 patients and 37 age-and gender-matched healthy controls were recruited for the study. The study was approved by the Institutional Review Board of Tianjin Medical University for the use of human subjects in biomedical research. All subjects or guardians signed consent forms before enrollment, and blood samples were collected.
Morning fasting venous blood (2 mL) was collected 1, 4, 7, 14, and 21 days after TBI using EDTA (0.5 mM final concentration) as an anticoagulant. Blood samples were also collected from age-and gender-matched healthy subjects to obtain baseline normal reference values, which were used to evaluate changes in circulating EPCs in patients with TBI. Blood samples were processed within 2 hrs after blood draw.
EPC Isolation and Measurements. To quantify EPCs in circulation, peripheral mononuclear cells were first isolated from blood samples as previously described (15) . Briefly, 2 mL of blood was subjected to a density gradient centrifugation at 300 ϫ g for 20 min at room temperature. The isolated cells were washed three times with phosphatebuffered saline (pH 7.2) and resuspended in 200 L of phosphate-buffered saline supplemented with 0.5% bovine serum albumin and 2 mM EDTA. The cells were then labeled with an R-phycoerythrin-conjugated monoclonal CD133 antibody (Miltenyi Biotech, Gladbach, Germany) or fluorescein isothiocyanateconjugated CD34 monoclonal antibody (BD Pharmingen, San Jose, CA) or both for 20 min at room temperature. We used two cellular markers to identify peripheral EPCs because CD34 recognizes stem cells of endothelial lineage, whereas CD133 primarily detects immature EPCs that are highly capable of differentiating into endothelial cells. The double staining will allow us to not only identify endothelial cells in circulation, but also determine the ratio of mature to immature cell populations, a measure that can potentially be used to gauge the patient's ability to repair the vasculature. Stained cells were washed with phosphate-buffered saline/bovine serum albumin and then analyzed by flow cytometry (BD FACS Calibur, BD Biosciences, San Jose, CA). Two isotype controls of R-phycoerythrin-and fluorescein isothiocyanate-conjugated mouse immunoglobulin G were used for background nonspecific binding. Cells were first run on forward and side scatter to select mononuclear cells to reduce signal noises from cell aggregates, platelets, and cellular debris. Three populations of cells were analyzed, CD34 ϩ , CD133 ϩ , and double-stained cells, and expressed as numbers of positive cells in each population. For double fluorescence detection, cells were first gated for their CD34 positivity and then for CD133 staining. EPCs were then detected as gated cells that were stained for fluorescein isothiocyanate-CD34 and Rphycoerythrin-CD133 and quantified as the number of EPCs per 2 ϫ 10 6 mononuclear cells (15) .
Clinical Assessment of Neurologic Recovery. All patients admitted were treated according to the international guidelines for TBI treatment. To our best knowledge, patients did not use medicines that are known to affect the level of circulating EPCs during the follow-up period. All patients were diagnosed on the basis of computed tomographic or magnetic resonance imaging scans that showed the evidence of intracranial hematoma, hemorrhage, and cerebral contusion. Patients were scored at admission by the Glasgow Coma Scale (GCS) and divided into mild (GCS score of [13] [14] [15] ) and moderate to severe (GCS score of Յ12) injury. The GCS score of survival patients was also monitored during the follow-up period to determine whether a patient had 1) improved (unchanged for those with a GCS score of 15 or showed improvement of Ͼ1 point) or 2) deteriorated (GCS score remained unchanged or decreased by Ͼ1 point) or 3) until the patient died.
Statistical Analysis. All statistical analyses were performed by a biostatistician who was blinded about demographic information, clin- Receiver operating characteristic curves and the areas under the curves for an increase in circulating EPCs were analyzed and used to predict neurologic recovery or short-term outcome as measured by the improvement of the GCS score. Repeated measures analysis of variance with the post hoc least significant difference test was used to compare the numbers of circulating EPCs at different time points between patients with improved and those with deteriorated outcomes. The analysis of mixedeffects models was used to assess the dynamic changes of circulating EPC numbers for pa-tients who survived and those who did not during the follow-up period.
The influence of the circulating EPC elevation in the first 7 days on neurologic recovery or short-term outcome was assessed by logistic regression analysis. Results were expressed as adjusted odds ratios with the corresponding 95% confidence interval. A p value of Ͻ.05 was considered to be statistically significant. All analyses were performed using the SPSS software (version 16.0, SPSS, Chicago, IL) or SAS statistical package (version 8.1, SAS Institute, Cary, NC).
RESULTS

Patients.
A total of 101 patients were initially recruited, but 84 patients were included in the final statistical analysis. Seventeen patients were excluded due to a large amount of blood transfusion, which interfered with the levels of patient-derived EPCs (data not shown). To address the concern of blood transfusion, we have conducted a pilot study and determined that the levels of circulating EPCs in patients who received Ͻ1800 mL of blood transfusion (mean 856 mL) were not statistically different from those without blood transfusion during the fol- Figure 2 . Changes of circulating endothelial progenitor cells (EPCs) after traumatic brain injury. EPC counts in peripheral blood samples were measured at five time points during a follow-up period of up to 21 days. Blood samples were also collected from 37 healthy subjects as controls to set the normal reference value for baseline levels of circulating EPCs (Student's t test, *p Ͻ .01). low-up period (Fig. 1A) . On the basis of this pilot study, patients who received Ͼ1800 mL of blood transfusion were excluded from the final analyses. The demographic information on the patients and controls is presented in Table 1 . Among 84 patients included in the data analyses, 57 underwent open surgery to remove hematoma and/or to relieve intracranial hypertension and 27 received nonsurgical treatments. There was no significant difference between subjects who underwent craniotomy and those without surgery (Fig. 1B) . As a result, we exclude surgery and blood transfusion of Ͻ1800 mL as confounding factors for data stratification.
Of the 84 patients analyzed, 69 patients survived and 15 died during the follow-up period. Among survival patients, the clinical conditions were improved in 62 patients and deteriorated in seven patients (in some analyses, death and deterioration were combined due to a limited number of cases). To determine the prognostic value of EPCs in peripheral blood samples, patients were divided into two categories of data analyses. The first was to show differences between survivors and nonsurvivors (analysis 1) and the second to show differences between improving and nonimproving (including death) patients (analysis 2) during the course of a follow-up period of 21 days.
Clinical variables of patients in the two categories are listed in Table 2 . GCS measured at admission and during follow-up was significantly lower for nonsurvival patients and patients with deteriorated conditions as compared to survival patients and those with improved clinical conditions. Blood glucose levels followed a similar trend, showing that patients who died of TBI and those with deteriorated conditions during the follow-up period had significantly higher blood glucose than survival patients and patients with improved clinical conditions.
Circulating EPC in Patients and Controls. The average level of circulating EPCs for all patients was significantly lower in the first 24 hrs after TBI as compared to that for healthy subjects. However, it was rapidly increased thereafter, reaching the plateau 7 days post-TBI and then gradually declining to the baseline level over the course of 2 wks (Fig. 2) .
The changes in circulating EPCs from day 1 to day 7 are shown in Figure 3A circulating EPCs during follow-up detected statistically different intercepts (p ϭ .034) and slopes (p ϭ .0015) between survival and nonsurvival patients.
For survival patients, the numbers of circulating EPCs on days 7, 14, and 21 were significantly higher for patients with improved conditions as compared to those with deteriorated conditions (p Ͻ .01, Fig. 3B ). More importantly, the magnitude of increase in circulating EPCs was markedly greater for patients with improved conditions as compared those with deteriorated conditions, who actually showed a steady decline in EPC levels during the follow-up period (Fig. 3C ). EPC counts in peripheral blood showed a steady increase over time for most patients with improved clinical conditions (Fig. 4A) , whereas they remained unchanged for those with deteriorated conditions during the same period (Fig. 4B ). Due to a lack of linearity, the number of circulating EPCs in the first 7 days was also analyzed by receiver operating characteristic curves and areas under the curve (Fig. 4C ). The analysis identified 41 EPCs per 10 6 mononuclear cells of blood sample as the cutoff point for a sensitive and specific outcome prediction (Fig. 4 , area under the curve 0.691, 95% confidence interval 0.581-0.802, p ϭ .008). The logistic regression analysis (Table 3) showed that a number of circulating EPCs of Ն41 per 10 6 mononuclear cells in the first 7 days independently predicts neurologic recovery (odds ratio 0.988, 95% confidence interval, 0.977-0.999, p ϭ .029) after adjustment for GCS score, body temperature, blood glucose at admission, and type of injury. More importantly, there is a significant positive correlation between circulating EPC numbers on day 7 and neurologic recovery ( Fig. 5 ; survivor vs. nonsurvivor, R 2 ϭ 0.1298, p Ͻ .001; improved vs. deteriorated, R 2 ϭ 0.0893, p Ͻ .001).
Furthermore, a Kaplan-Meier survival estimate based on the magnitude of increase in circulating EPCs in the first 7 days finds that there is a higher hospital mortality for patients whose circulating ECP level is Յ41 EPCs per 10 6 mononuclear cells in the first 7 days (Fig. 6 ).
DISCUSSION
Since the first report by Asahara et al in 1997 (1) , EPCs isolated from peripheral blood have been the focus of extensive studies to characterize their phenotype and biochemical properties and, more importantly, to evaluate them as a potential therapeutic and diagnostic tool. Here, we present data from a clinical study to specifically examine the dynamic change of EPC counts in peripheral blood and its prognostic value for TBI. Consistent with our early report of a smaller cohort of patients (15) , EPCs in peripheral blood were first suppressed to a level that is 72.6% of the normal reference within the first 24 -48 hrs of trauma and then increased steadily, reaching a peak level of 173.1% of the normal reference at approximately 7 days before declining to baseline (Fig. 2) . The initial EPC suppression is also reported in patients with ischemic stroke (4) and is likely to be consumptive in nature as circulating EPCs . Relationship between circulating endothelial progenitor cells (EPCs) and early hospital mortality. The Kaplan-Meier estimate of survival according to the magnitude of elevated levels of peripheral EPC counts in the first 7 days was performed. Although most patients showed an increase in EPC counts during the first 7 days, there was a higher rate of hospital mortality for patients whose peripheral ECP counts increased but remained below 41 per 10 6 mononuclear cells as compared to those with higher EPC counts measured during the first 7 days after traumatic brain injury (*p Ͻ .05). accumulate at the injured vascular beds. The notion is supported by our recent observation that CD34 ϩ hematopoietic stem cells (EPCs are a subpopulation of CD34 ϩ cells) accumulate in the injured cerebral tissue and are found to be incorporated into new vasculature in TBI rats (16) . The subsequent increase in EPC levels likely result from the bone marrow mobilization in response to TBI as well as the consumptive EPC deficiency. One of the key findings of the current study is that the increase in circulating EPCs is associated with an improved clinical outcome in TBI patients ( Figs. 3C and Fig. 5 ). This association demonstrates the importance of circulating EPCs in vascular repairs. Traumatic injury can cause brain damage by direct mechanical impact but more importantly by ischemic injury secondary to intracranial hypertension, tissue hypoxia, and microthrombosis. The damaged cells could subsequently release active substances such as proinflammatory cytokines to propagate tissue injury. It is therefore critical to reestablish blood circulation early. There is abundant evidence to suggest that peripheral EPCs actively participate in tissue repair, largely through vascular repair and angiogenesis to restore blood flow to the injured area. Circulating ECPs have been found to rapidly accumulate in the ischemic area to form new vessels and improve regional blood flow (17) . The number of circulating EPCs is inversely correlated with the size of the ischemic area (4) . Most clinical observations indicate that the secondary injury occurs approximately 3-5 days after trauma, when tissue repair is also most active (18) . The most significant neural improvements are commonly achieved by the third week. This course of vascular and neural repairs coincides with the pattern of changes in circulating EPC counts (Fig.  3C) , with the highest EPC levels found approximately 7 days after trauma.
A critical question is whether any of these change in circulating EPCs correlates with the clinical course, treatment, and prognosis of patients. Our data suggest a strong correlation between circulating EPCs and clinical outcomes. Patients with worsened clinical outcome or death had a persistently low level of EPCs, with limited or no increase observed for patients who had improved outcomes ( Figs. 3 and 5 ), suggesting that EPCs may not have been sufficiently mobilized. Factors that limit or prevent EPC mobilization remain to be identified, but we find that the lack of insufficient EPC mobilization is not related to any particular type of injury or treatment. Consistent with the conclusion, the number of circulating EPCs has previously been demonstrated to correlate with the Framingham risk score for ischemic stroke (19) . Yip et al (20) also show that patients with severe neurologic dysfunction (National Institutes of Health Stroke score of Ն12) have lower peripheral EPCs 48 hrs post-ischemic stroke.
In summary, we have demonstrated a close correlation between the levels of circulating EPCs and short-term clinical outcomes of 84 patients with TBI. The EPC levels in peripheral blood were found to be first suppressed in the acute phase (first 24 -48 hrs) and then rapidly increased, reaching the maximal level 7 days after trauma. Consistently low circulating EPCs were associated with worsened clinical conditions or death. Furthermore, the level of circulating EPCs was not affected by the type of injury and treatments. These results suggest that circulating EPCs may serve as a clinical prognostic marker for TBI. The current study is limited to correlating EPCs to short-term outcomes but can be further expanded into a multicentered study to develop a better regression model and to evaluate the quality of life for surviving patients in a longer follow-up period. They also demonstrate that EPC transplantation or therapeutic means to increase EPC mobilization may improve patient recovery from severe TBI.
